[Effectiveness of Live Attenuated Influenza Vaccines and Trivalent Inactivated Influenza Vaccines against confirmed Influenza In Children and Adolescents in Saxony-Anhalt, 2012/13].
Identifieur interne : 000116 ( Main/Exploration ); précédent : 000115; suivant : 000117[Effectiveness of Live Attenuated Influenza Vaccines and Trivalent Inactivated Influenza Vaccines against confirmed Influenza In Children and Adolescents in Saxony-Anhalt, 2012/13].
Auteurs : N. Hermann [Autriche]Source :
- Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) [ 1439-4421 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Allemagne (épidémiologie), Enfant, Enfant d'âge préscolaire, Facteurs de risque, Femelle, Grippe humaine (), Grippe humaine (diagnostic), Grippe humaine (épidémiologie), Humains, Mâle, Prévalence, Répartition par sexe, Répartition par âge, Résultat thérapeutique, Vaccins antigrippaux (administration et posologie), Vaccins atténués (administration et posologie), Vaccins inactivés (administration et posologie), Études rétrospectives.
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins atténués, Vaccins inactivés.
- diagnostic : Grippe humaine.
- épidémiologie : Allemagne, Grippe humaine.
- Adolescent, Enfant, Enfant d'âge préscolaire, Facteurs de risque, Femelle, Grippe humaine, Humains, Mâle, Prévalence, Répartition par sexe, Répartition par âge, Résultat thérapeutique, Études rétrospectives.
English descriptors
- KwdEn :
- Adolescent, Age Distribution, Child, Child, Preschool, Female, Germany (epidemiology), Humans, Influenza Vaccines (administration & dosage), Influenza, Human (diagnosis), Influenza, Human (epidemiology), Influenza, Human (therapy), Male, Prevalence, Retrospective Studies, Risk Factors, Sex Distribution, Treatment Outcome, Vaccines, Attenuated (administration & dosage), Vaccines, Inactivated (administration & dosage).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Attenuated, Vaccines, Inactivated.
- diagnosis : Influenza, Human.
- epidemiology : Germany, Influenza, Human.
- therapy : Influenza, Human.
- Adolescent, Age Distribution, Child, Child, Preschool, Female, Humans, Male, Prevalence, Retrospective Studies, Risk Factors, Sex Distribution, Treatment Outcome.
Abstract
Since 2012, there are not only trivalent inactivated influenza vaccines (TIV) but also live attenuated influenza vaccines (LAIV) available for children aged 2-17 years in Germany. The Saxony-Anhalt State Office for Consumer Protection conducted a test-negative case-control-study. The aim of the study was to identify the effectiveness of LAIV and TIV against a confirmed influenza diagnosis in children and adolescents in Saxony-Anhalt in the season 2012/13. The children had nasal swabs taken, which were further diagnosed in a laboratory using the PCR method. 834 patients of 15 voluntarily participating paediatric surgeries in Saxony-Anhalt were analysed by multivariate logistic regression with STATA 12. Controlling for age group, gender and month of the disease's onset showed an effectiveness of all vaccines amongst the 2-17 years old (38% with 95% CI: 0.8-61%; p=0.046). A differentiation according to LAIV and TIV demonstrated a significant effectiveness for LAIV (84%) in children of all ages (95% CI: 45-95%, p=0.004). After stratification for age groups LAIV was proven efficient in children aged 2-6 years (90% with 95% CI: 20-99%, p=0.03), whilst it led to a non-significant result in children aged 7-17 years (74% with 95% CI: -32-95%, p=0.106). There was no significant effectiveness of TIV seen in any age group.The Saxony-Anhalt State Office for Consumer Protection endorses the use of LAIV in children in accordance with the STIKO recommendations, as long as no contraindication is evident.
DOI: 10.1055/s-0035-1554685
PubMed: 26227384
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Effectiveness of Live Attenuated Influenza Vaccines and Trivalent Inactivated Influenza Vaccines against confirmed Influenza In Children and Adolescents in Saxony-Anhalt, 2012/13].</title><author><name sortKey="Hermann, N" sort="Hermann, N" uniqKey="Hermann N" first="N" last="Hermann">N. Hermann</name><affiliation wicri:level="3"><nlm:affiliation>Fachhochschule bfi Wien, Wien.</nlm:affiliation><country>Autriche</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName><wicri:orgArea>Fachhochschule bfi Wien</wicri:orgArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26227384</idno><idno type="pmid">26227384</idno><idno type="doi">10.1055/s-0035-1554685</idno><idno type="wicri:Area/Main/Corpus">000120</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000120</idno><idno type="wicri:Area/Main/Curation">000120</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000120</idno><idno type="wicri:Area/Main/Exploration">000120</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Effectiveness of Live Attenuated Influenza Vaccines and Trivalent Inactivated Influenza Vaccines against confirmed Influenza In Children and Adolescents in Saxony-Anhalt, 2012/13].</title><author><name sortKey="Hermann, N" sort="Hermann, N" uniqKey="Hermann N" first="N" last="Hermann">N. Hermann</name><affiliation wicri:level="3"><nlm:affiliation>Fachhochschule bfi Wien, Wien.</nlm:affiliation><country>Autriche</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName><wicri:orgArea>Fachhochschule bfi Wien</wicri:orgArea></affiliation></author></analytic><series><title level="j">Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</title><idno type="eISSN">1439-4421</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Age Distribution</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Germany (epidemiology)</term><term>Humans</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (diagnosis)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (therapy)</term><term>Male</term><term>Prevalence</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Sex Distribution</term><term>Treatment Outcome</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Inactivated (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Allemagne (épidémiologie)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de risque</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (diagnostic)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Mâle</term><term>Prévalence</term><term>Répartition par sexe</term><term>Répartition par âge</term><term>Résultat thérapeutique</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins atténués (administration et posologie)</term><term>Vaccins inactivés (administration et posologie)</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Germany</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Age Distribution</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Sex Distribution</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de risque</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Prévalence</term><term>Répartition par sexe</term><term>Répartition par âge</term><term>Résultat thérapeutique</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since 2012, there are not only trivalent inactivated influenza vaccines (TIV) but also live attenuated influenza vaccines (LAIV) available for children aged 2-17 years in Germany. The Saxony-Anhalt State Office for Consumer Protection conducted a test-negative case-control-study. The aim of the study was to identify the effectiveness of LAIV and TIV against a confirmed influenza diagnosis in children and adolescents in Saxony-Anhalt in the season 2012/13. The children had nasal swabs taken, which were further diagnosed in a laboratory using the PCR method. 834 patients of 15 voluntarily participating paediatric surgeries in Saxony-Anhalt were analysed by multivariate logistic regression with STATA 12. Controlling for age group, gender and month of the disease's onset showed an effectiveness of all vaccines amongst the 2-17 years old (38% with 95% CI: 0.8-61%; p=0.046). A differentiation according to LAIV and TIV demonstrated a significant effectiveness for LAIV (84%) in children of all ages (95% CI: 45-95%, p=0.004). After stratification for age groups LAIV was proven efficient in children aged 2-6 years (90% with 95% CI: 20-99%, p=0.03), whilst it led to a non-significant result in children aged 7-17 years (74% with 95% CI: -32-95%, p=0.106). There was no significant effectiveness of TIV seen in any age group.The Saxony-Anhalt State Office for Consumer Protection endorses the use of LAIV in children in accordance with the STIKO recommendations, as long as no contraindication is evident. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26227384</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-4421</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</Title><ISOAbbreviation>Gesundheitswesen</ISOAbbreviation></Journal><ArticleTitle>[Effectiveness of Live Attenuated Influenza Vaccines and Trivalent Inactivated Influenza Vaccines against confirmed Influenza In Children and Adolescents in Saxony-Anhalt, 2012/13].</ArticleTitle><Pagination><MedlinePgn>499-501</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0035-1554685</ELocationID><Abstract><AbstractText>Since 2012, there are not only trivalent inactivated influenza vaccines (TIV) but also live attenuated influenza vaccines (LAIV) available for children aged 2-17 years in Germany. The Saxony-Anhalt State Office for Consumer Protection conducted a test-negative case-control-study. The aim of the study was to identify the effectiveness of LAIV and TIV against a confirmed influenza diagnosis in children and adolescents in Saxony-Anhalt in the season 2012/13. The children had nasal swabs taken, which were further diagnosed in a laboratory using the PCR method. 834 patients of 15 voluntarily participating paediatric surgeries in Saxony-Anhalt were analysed by multivariate logistic regression with STATA 12. Controlling for age group, gender and month of the disease's onset showed an effectiveness of all vaccines amongst the 2-17 years old (38% with 95% CI: 0.8-61%; p=0.046). A differentiation according to LAIV and TIV demonstrated a significant effectiveness for LAIV (84%) in children of all ages (95% CI: 45-95%, p=0.004). After stratification for age groups LAIV was proven efficient in children aged 2-6 years (90% with 95% CI: 20-99%, p=0.03), whilst it led to a non-significant result in children aged 7-17 years (74% with 95% CI: -32-95%, p=0.106). There was no significant effectiveness of TIV seen in any age group.The Saxony-Anhalt State Office for Consumer Protection endorses the use of LAIV in children in accordance with the STIKO recommendations, as long as no contraindication is evident. </AbstractText><CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fachhochschule bfi Wien, Wien.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Wirksamkeit des trivalenten Lebendimpfstoffes und der trivalenten Totimpfstoffe gegen eine laborbestätigte Influenza bei Kindern und Jugendlichen in Sachsen-Anhalt, 2012/13.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Gesundheitswesen</MedlineTA><NlmUniqueID>9204210</NlmUniqueID><ISSNLinking>0941-3790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26227384</ArticleId><ArticleId IdType="doi">10.1055/s-0035-1554685</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li></country><region><li>Vienne (Autriche)</li></region><settlement><li>Vienne (Autriche)</li></settlement></list><tree><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Hermann, N" sort="Hermann, N" uniqKey="Hermann N" first="N" last="Hermann">N. Hermann</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000116 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000116 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26227384
|texte= [Effectiveness of Live Attenuated Influenza Vaccines and Trivalent Inactivated Influenza Vaccines against confirmed Influenza In Children and Adolescents in Saxony-Anhalt, 2012/13].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26227384" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |